402 related articles for article (PubMed ID: 26530743)
1. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).
Videtic GM; Hu C; Singh AK; Chang JY; Parker W; Olivier KR; Schild SE; Komaki R; Urbanic JJ; Timmerman RD; Choy H
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):757-64. PubMed ID: 26530743
[TBL] [Abstract][Full Text] [Related]
2. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
Videtic GM; Paulus R; Singh AK; Chang JY; Parker W; Olivier KR; Timmerman RD; Komaki RR; Urbanic JJ; Stephans KL; Yom SS; Robinson CG; Belani CP; Iyengar P; Ajlouni MI; Gopaul DD; Gomez Suescun JB; McGarry RC; Choy H; Bradley JD
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1077-1084. PubMed ID: 30513377
[TBL] [Abstract][Full Text] [Related]
3. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H
JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
6. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
7. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.
Temming S; Kocher M; Stoelben E; Hagmeyer L; Chang DH; Frank K; Hekmat K; Wolf J; Baus WW; Semrau R; Baues C; Marnitz S
Strahlenther Onkol; 2018 Feb; 194(2):91-97. PubMed ID: 28812120
[TBL] [Abstract][Full Text] [Related]
9. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
Fakiris AJ; McGarry RC; Yiannoutsos CT; Papiez L; Williams M; Henderson MA; Timmerman R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):677-82. PubMed ID: 19251380
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
[TBL] [Abstract][Full Text] [Related]
13. One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.
Singh AK; Gomez-Suescun JA; Stephans KL; Bogart JA; Hermann GM; Tian L; Groman A; Videtic GM
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):752-759. PubMed ID: 31445956
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy for inoperable early stage lung cancer.
Timmerman R; Paulus R; Galvin J; Michalski J; Straube W; Bradley J; Fakiris A; Bezjak A; Videtic G; Johnstone D; Fowler J; Gore E; Choy H
JAMA; 2010 Mar; 303(11):1070-6. PubMed ID: 20233825
[TBL] [Abstract][Full Text] [Related]
15. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.
Stephans KL; Djemil T; Reddy CA; Gajdos SM; Kolar M; Mason D; Murthy S; Rice TW; Mazzone P; Machuzak M; Mekhail T; Videtic GM
J Thorac Oncol; 2009 Aug; 4(8):976-82. PubMed ID: 19633473
[TBL] [Abstract][Full Text] [Related]
16. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Koshy M; Malik R; Weichselbaum RR; Sher DJ
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
[TBL] [Abstract][Full Text] [Related]
17. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.
Nagata Y; Hiraoka M; Shibata T; Onishi H; Kokubo M; Karasawa K; Shioyama Y; Onimaru R; Kozuka T; Kunieda E; Saito T; Nakagawa K; Hareyama M; Takai Y; Hayakawa K; Mitsuhashi N; Ishikura S
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):989-96. PubMed ID: 26581137
[TBL] [Abstract][Full Text] [Related]
18. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A; Wierzbicki M; Parpia S; Wright JR; Tsakiridis TK; Okawara GS; Kundapur V; Bujold A; Ahmed N; Hirmiz K; Kurien E; Filion E; Gabos Z; Faria S; Louie AV; Owen T; Wai E; Ramchandar K; Chan EK; Julian J; Cline K; Whelan TJ
Clin Lung Cancer; 2017 Mar; 18(2):250-254. PubMed ID: 27876603
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure.
Andratschke N; Zimmermann F; Boehm E; Schill S; Schoenknecht C; Thamm R; Molls M; Nieder C; Geinitz H
Radiother Oncol; 2011 Nov; 101(2):245-9. PubMed ID: 21724287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
